Back
Serum Biomarkers for Predicting Clinical Outcomes of Patients with Coronavirus Disease 2019
Inventors
Prof. WU Ka Kei
Department
Department of Anaesthesia and Intensive Care
Key Problem and Market Opportunity
- COVID-19 has rapidly spread worldwide, causing significant mortality.
- However, there is currently no prognostic biomarkers to identify patients with COVID-19 at high risk of clinical deterioration to predict the need for intensive monitoring and early treatment
- To develop a biomarker for predicting progression to severe COVID-19
Key Advantages of the Technology
- Biological process X was aberrantly upregulated in peripheral blood mononuclear cells of COVID-19 patients
- Decreased serum concentrations of marker Y, which is degraded by the biological process X, were associated with the requirement for supplemental oxygen therapy or other respiratory support in COVID-19 patients
- Marker Y predicted moderate-to-severe COVID-19 independent of age, sex and clinical risk score
Potential Applications
- Currently, no existing biomarker available in the market
- Prognostic biomarker to predict the needs of patients with COVID-19 for extensive monitoring and early treatment
Photos
Tabulate result on the odds ratio (OR) and its significance between Marker Y with the clinical risk score
Serum Biomarkers for Predicting Clinical Outcomes of Patients with Coronavirus Disease 2019
Inventors
Prof. WU Ka Kei
Department
Department of Anaesthesia and Intensive Care
Key Problem and Market Opportunity
- COVID-19 has rapidly spread worldwide, causing significant mortality.
- However, there is currently no prognostic biomarkers to identify patients with COVID-19 at high risk of clinical deterioration to predict the need for intensive monitoring and early treatment
- To develop a biomarker for predicting progression to severe COVID-19
Key Advantages of the Technology
- Biological process X was aberrantly upregulated in peripheral blood mononuclear cells of COVID-19 patients
- Decreased serum concentrations of marker Y, which is degraded by the biological process X, were associated with the requirement for supplemental oxygen therapy or other respiratory support in COVID-19 patients
- Marker Y predicted moderate-to-severe COVID-19 independent of age, sex and clinical risk score
Potential Applications
- Currently, no existing biomarker available in the market
- Prognostic biomarker to predict the needs of patients with COVID-19 for extensive monitoring and early treatment
Photos
Tabulate result on the odds ratio (OR) and its significance between Marker Y with the clinical risk score
Categories
Molecular Diagnostics
CUHK Tech ID
P-2020-0961
Patents
US63/038,673
Enquiry Contacts